Clinical Trial

Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical research study is to find the recommended dose level and recommended number of injections of the study agent DNX-2401 that can be given to patients with metastatic melanoma that have intracranial and/or extracranial lesions.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-02-26; most recent amendment 2026-04-30.
Trial Details
NCT Number NCT07444606
Lead Sponsor M.D. Anderson Cancer Center
Conditions Melanoma
Enrollment 50 participants
Start Date 2026-08-31
Primary Completion 2027-01-30 (estimated)
Study Completion 2029-01-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-06